Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Deals Biosimilars Middle East and Africa

Another Denosumab Deal For mAbxience In MEA

MS Pharma Is Set To Register And Market The Prolia/Xgeva Biosimilar In MEA Markets

  • News

Executive Summary

A further licensing deal for biosimilar denosumab has been struck by mAbxience, with MS Pharma set to register and market the Prolia/Xgeva rival in “select MEA markets.”

You may also be interested in...



Deal Watch: Graphite Exits Via Reverse Merger With Presbyopia Specialist LENZ

Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.

Abbott To Take mAbxience Biosimilars To Emerging Markets From 2025

European biosimilars specialist mAbxience will hand several of its biosimilars over to the global commercialization expertise of Abbott under a new agreement signed between the firms.

Mabxience Sets Out Investment Plans Under Fresenius Ownership

Unveiling plans to install a new bioreactor at its Genhelix site in Spain, mAbxience is bolstering its biosimilars manufacturing capabilities and CDMO capacity under the majority ownership of Fresenius Kabi.

Table

View full table

Related Content

Generics Bulletin

Topics

Related Companies

Tags:
Deals Biosimilars Middle East and Africa
Latest Headlines

Numerous US Approvals Received By Lupin Following 278% Quarterly Profits Raise

Merck As Anchor, Scale As Lever, Aurobindo Looks To Spar With Lonza, WuXi Group

Fresenius And Formycon File Ustekinumab In US

What’s Next? Five Things To Look Out For In December

See All
UsernamePublicRestriction

Register

GB153108

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By